Answers are grounded in this paper and cite their sources.
The estrogen-related receptor alpha (ERRalpha) is a potential target for activation in the treatment of metabolic disease. To date, no small-molecule agonists of ERRalpha have been identified despite several high-throughput screening campaigns. We describe the synthesis and profiling of a small array of compounds designed on the basis of a previously reported agonist-bound crystal structure of the closely related receptor ERRgamma. The results suggest that ERRalpha may be intractable as a direct target for pharmacologic activation.
No takes yet. Share an insight, caveat, or question.
Hyatt et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: